|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AASDH |
Gene summary for AASDH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AASDH | Gene ID | 132949 |
| Gene name | aminoadipate-semialdehyde dehydrogenase | |
| Gene Alias | ACSF4 | |
| Cytomap | 4q12 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | B4E2K0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 132949 | AASDH | LZE4T | Human | Esophagus | ESCC | 1.95e-02 | 1.82e-01 | 0.0811 |
| 132949 | AASDH | P1T-E | Human | Esophagus | ESCC | 2.74e-05 | 2.00e-01 | 0.0875 |
| 132949 | AASDH | P2T-E | Human | Esophagus | ESCC | 4.99e-21 | 4.00e-01 | 0.1177 |
| 132949 | AASDH | P4T-E | Human | Esophagus | ESCC | 2.44e-15 | 3.46e-01 | 0.1323 |
| 132949 | AASDH | P5T-E | Human | Esophagus | ESCC | 1.72e-06 | 9.92e-02 | 0.1327 |
| 132949 | AASDH | P8T-E | Human | Esophagus | ESCC | 4.98e-15 | 3.17e-01 | 0.0889 |
| 132949 | AASDH | P10T-E | Human | Esophagus | ESCC | 1.49e-09 | 1.35e-01 | 0.116 |
| 132949 | AASDH | P11T-E | Human | Esophagus | ESCC | 8.96e-03 | 1.22e-01 | 0.1426 |
| 132949 | AASDH | P12T-E | Human | Esophagus | ESCC | 1.61e-15 | 3.23e-01 | 0.1122 |
| 132949 | AASDH | P15T-E | Human | Esophagus | ESCC | 1.03e-09 | 1.23e-01 | 0.1149 |
| 132949 | AASDH | P16T-E | Human | Esophagus | ESCC | 1.51e-20 | 3.34e-01 | 0.1153 |
| 132949 | AASDH | P20T-E | Human | Esophagus | ESCC | 3.94e-04 | 9.31e-02 | 0.1124 |
| 132949 | AASDH | P21T-E | Human | Esophagus | ESCC | 6.25e-20 | 3.52e-01 | 0.1617 |
| 132949 | AASDH | P22T-E | Human | Esophagus | ESCC | 6.75e-18 | 2.28e-01 | 0.1236 |
| 132949 | AASDH | P23T-E | Human | Esophagus | ESCC | 2.45e-03 | 9.31e-02 | 0.108 |
| 132949 | AASDH | P24T-E | Human | Esophagus | ESCC | 5.52e-04 | 8.89e-02 | 0.1287 |
| 132949 | AASDH | P26T-E | Human | Esophagus | ESCC | 1.16e-12 | 2.95e-01 | 0.1276 |
| 132949 | AASDH | P27T-E | Human | Esophagus | ESCC | 4.81e-07 | 2.26e-01 | 0.1055 |
| 132949 | AASDH | P28T-E | Human | Esophagus | ESCC | 3.86e-20 | 5.09e-01 | 0.1149 |
| 132949 | AASDH | P30T-E | Human | Esophagus | ESCC | 1.12e-11 | 3.39e-01 | 0.137 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
| GO:00065757 | Esophagus | ESCC | cellular modified amino acid metabolic process | 112/8552 | 188/18723 | 8.31e-05 | 6.06e-04 | 112 |
| GO:00086525 | Esophagus | ESCC | cellular amino acid biosynthetic process | 51/8552 | 76/18723 | 1.30e-04 | 8.88e-04 | 51 |
| GO:00067671 | Esophagus | ESCC | water-soluble vitamin metabolic process | 41/8552 | 59/18723 | 1.84e-04 | 1.17e-03 | 41 |
| GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
| GO:00067661 | Esophagus | ESCC | vitamin metabolic process | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
| GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
| GO:19016075 | Esophagus | ESCC | alpha-amino acid biosynthetic process | 45/8552 | 68/18723 | 5.13e-04 | 2.84e-03 | 45 |
| GO:00090674 | Esophagus | ESCC | aspartate family amino acid biosynthetic process | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
| GO:001605312 | Liver | Cirrhotic | organic acid biosynthetic process | 139/4634 | 316/18723 | 4.28e-14 | 3.83e-12 | 139 |
| GO:004639412 | Liver | Cirrhotic | carboxylic acid biosynthetic process | 137/4634 | 314/18723 | 1.40e-13 | 1.14e-11 | 137 |
| GO:19016051 | Liver | Cirrhotic | alpha-amino acid metabolic process | 82/4634 | 195/18723 | 7.72e-08 | 2.30e-06 | 82 |
| GO:000652011 | Liver | Cirrhotic | cellular amino acid metabolic process | 103/4634 | 284/18723 | 8.88e-06 | 1.30e-04 | 103 |
| GO:00086521 | Liver | Cirrhotic | cellular amino acid biosynthetic process | 36/4634 | 76/18723 | 1.55e-05 | 2.11e-04 | 36 |
| GO:19016071 | Liver | Cirrhotic | alpha-amino acid biosynthetic process | 33/4634 | 68/18723 | 1.84e-05 | 2.49e-04 | 33 |
| GO:000657511 | Liver | Cirrhotic | cellular modified amino acid metabolic process | 70/4634 | 188/18723 | 9.04e-05 | 9.69e-04 | 70 |
| GO:00090661 | Liver | Cirrhotic | aspartate family amino acid metabolic process | 21/4634 | 49/18723 | 4.13e-03 | 2.21e-02 | 21 |
| GO:00090671 | Liver | Cirrhotic | aspartate family amino acid biosynthetic process | 11/4634 | 21/18723 | 5.89e-03 | 2.95e-02 | 11 |
| GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
| GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AASDH | SNV | Missense_Mutation | c.1094N>G | p.Ser365Cys | p.S365C | Q4L235 | protein_coding | tolerated(0.08) | benign(0.096) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| AASDH | SNV | Missense_Mutation | novel | c.74N>C | p.Cys25Ser | p.C25S | Q4L235 | protein_coding | tolerated(0.23) | benign(0.012) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
| AASDH | SNV | Missense_Mutation | c.1619A>G | p.Tyr540Cys | p.Y540C | Q4L235 | protein_coding | deleterious(0.03) | possibly_damaging(0.533) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AASDH | SNV | Missense_Mutation | rs773718786 | c.1996N>C | p.Ile666Leu | p.I666L | Q4L235 | protein_coding | tolerated(0.28) | benign(0.001) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| AASDH | SNV | Missense_Mutation | novel | c.2620N>G | p.His874Asp | p.H874D | Q4L235 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-WT-AB41-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| AASDH | insertion | Frame_Shift_Ins | novel | c.2159_2160insT | p.Lys720AsnfsTer23 | p.K720Nfs*23 | Q4L235 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| AASDH | insertion | Frame_Shift_Ins | novel | c.2158_2159insTAAGTCATCTACAACTGTGTACATTGGTTCCCATTCTC | p.Lys720IlefsTer16 | p.K720Ifs*16 | Q4L235 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| AASDH | SNV | Missense_Mutation | novel | c.1577G>A | p.Gly526Asp | p.G526D | Q4L235 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| AASDH | SNV | Missense_Mutation | c.448N>A | p.Glu150Lys | p.E150K | Q4L235 | protein_coding | tolerated(0.17) | benign(0.192) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AASDH | SNV | Missense_Mutation | c.761N>T | p.Ser254Leu | p.S254L | Q4L235 | protein_coding | deleterious(0) | possibly_damaging(0.735) | TCGA-FU-A3YQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |